0 181

Cited 0 times in

Cited 0 times in

Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045

Authors
 Kim, Yoo-Na  ;  Joung, Je-Gun  ;  Park, Eunhyang  ;  Kim, Jae-Weon  ;  Lee, Jung Bok  ;  Lim, Jinyeong  ;  Kim, Sunghoon  ;  Choi, Chel Hun  ;  Kim, Hee Seung  ;  Chung, Jongsuk  ;  Kim, Byoung-Gie  ;  Lee, Jung-Yun 
Citation
 INTERNATIONAL JOURNAL OF CANCER, Vol.154(4) : 764-765, 2024-02 
Journal Title
INTERNATIONAL JOURNAL OF CANCER
ISSN
 0020-7136 
Issue Date
2024-02
Abstract
[No abstract available]
DOI
10.1002/ijc.34786
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sung Hoon(김성훈) ORCID logo https://orcid.org/0000-0002-1645-7473
Kim, Yoo‐Na(김유나)
Park, Eunhyang(박은향) ORCID logo https://orcid.org/0000-0003-2658-5054
Lee, Jung-Yun(이정윤) ORCID logo https://orcid.org/0000-0001-7948-1350
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/204225
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links